#SRDX ANALYST COVERAGE FULL#

SurModics partners with the world's leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. We will later highlight each of the following areas and review SurModics as an investment for the future:ġ) The future of medical devices and business expansionĢ) New opportunities and investments for SRDXģ) The economics of the SRDX business and industry overview Developing relationships with major customers and increased pricing of products will lead to solid growth on both the top and bottom line. SurModics is tied to the high growth area of medical devices that are used in minor procedures as well as major surgeries. We strongly feel that this company has the potential to see huge upside over the next year and a half as it takes advantage of new market opportunities and continues to drive growth in the company's existing medical device businesses. With this in mind, we value SurModics at $26.00 by year-end of 2013 and $30.00 by June 30, 2014, an increase of 25% from current levels. The company has a market cap of $347.40 Million and reports the next quarter on November 4, 2013.

#SRDX ANALYST COVERAGE FULL#

Investors and Wall Street have failed to realize the full value in this company because of the small market cap and lack of coverage, but we believe that the stock will start to break out as the company has improving fundamentals and business prospects beyond 2013 and revenue will see a dramatic increase after the materialization of major contracts and partnerships. Below is our introduction into the business model, the strengths, and the current buying opportunity that exists for SurModics as the stock has traded relatively flat over the course of 2013 and is about 16% off of April highs.

SurModics ( NASDAQ: SRDX) is a highly undervalued and unrecognized company with huge potential on an international level in a business with high growth prospects as population around the world continues to age.

Srdx analyst coverage